Meropenem Aurovit (Meropenem)

Meropenem Aurovit is a broad‑spectrum carbapenem used to treat severe bacterial infections across several organ systems.

• Complicated intra‑abdominal infections: provides bacterial eradication and clinical cure.
• Complicated skin and soft tissue infections: eliminates resistant Gram‑negative and Gram‑positive pathogens.
• Community‑acquired pneumonia: achieves rapid bacterial clearance.
• Hospital‑acquired pneumonia: targets multidrug‑resistant organisms.
• Meningitis: penetrates the cerebrospinal fluid to treat central nervous system infections.
• Sepsis: offers systemic antibacterial activity in critically ill patients.

• Meropenem inhibits bacterial cell wall synthesis by binding with high affinity to penicillin‑binding proteins. This binding disrupts the cross‑linking of peptidoglycan strands, weakening the cell wall and leading to osmotic lysis of susceptible bacteria, including many Gram‑negative, Gram‑positive, and anaerobic organisms.

Adverse reactions may occur with any intravenous antibiotic and should be monitored during therapy.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: may be watery and self‑limiting.
• Rash: erythematous skin eruption.
• Headache: transient and usually resolves.
• Elevated liver enzymes: transient increase in ALT/AST.
• Injection site phlebitis: local irritation at the infusion site.

Serious or Rare Side Effects

• Seizures: especially in patients with renal impairment or CNS disorders.
• Clostridioides difficile colitis: severe diarrhea due to bacterial overgrowth.
• Anaphylaxis: acute hypersensitivity reaction requiring emergency care.
• Severe neutropenia: marked reduction in white blood cells.
• Renal toxicity: acute kidney injury in susceptible individuals.
• Hypersensitivity reactions: including serum sickness‑like manifestations.

Use meropenem with caution, adhering to clinical guidelines and patient monitoring.

• Renal function assessment: adjust dose in patients with impaired clearance.
• Hypersensitivity screening: avoid in individuals with known carbapenem allergy.
• Pregnancy considerations: safety not established; weigh benefits against potential risks.
• Seizure risk monitoring: observe patients with CNS disorders or high doses.
• Concomitant valproic acid: monitor for reduced antiepileptic levels.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with other medications, requiring attention to dosing and monitoring.

Major Interactions (Avoid)

• Valproic acid: meropenem reduces serum concentrations, risking seizure breakthrough.
• Warfarin: may enhance anticoagulant effect, increasing INR.
• Aminoglycosides: combined use can heighten nephrotoxicity.

Moderate Interactions (Monitor Closely)

• Diuretics: may affect electrolyte balance during therapy.
• NSAIDs: concurrent use can increase risk of renal impairment.
• Other antibiotics: potential antagonism when combined with bacteriostatic agents.